Somatostatin Receptor Expression in Renal Cell Carcinoma—A New Front in the Diagnostics and Treatment of Renal Cell Carcinoma

Clinical Practice Points Renal cell carcinoma (RCC) has a poor prognosis and is difficult to treat because of its ability to spread asymptomatically and its resistance to chemotherapy. In this patient series, we report that RCC metastases can be identified using gallium-68 (68Ga)-edotreotide (DOTATO...

Full description

Saved in:
Bibliographic Details
Published in:Clinical genitourinary cancer 2018-06, Vol.16 (3), p.e517-e520
Main Authors: Höög, Anders, Kjellman, Magnus, Mattsson, Per, Juhlin, C.Christofer, Shabo, Ivan
Format: Article
Language:English
Subjects:
Aged
Carcinoma, Renal Cell - diagnostic imaging
Carcinoma, Renal Cell - metabolism
Carcinoma, Renal Cell - surgery
Computed tomography
DOTATOC
Gene Expression
Humans
Kidney Neoplasms - diagnostic imaging
Kidney Neoplasms - metabolism
Kidney Neoplasms - surgery
Male
Medicin och hälsovetenskap
Neoplasm Metastasis
Octreotide - administration & dosage
Octreotide - analogs & derivatives
Organometallic Compounds - administration & dosage
Positron emission tomography
Positron Emission Tomography Computed Tomography - methods
RCC
Receptors, Somatostatin - metabolism
Sensitivity and Specificity
SSTR-2
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Clinical Practice Points Renal cell carcinoma (RCC) has a poor prognosis and is difficult to treat because of its ability to spread asymptomatically and its resistance to chemotherapy. In this patient series, we report that RCC metastases can be identified using gallium-68 (68Ga)-edotreotide (DOTATOC) positron emission tomography/computed tomography (PET/CT). Immunostaining of tumor tissue from primary RCC tumors and their matched adrenal, pancreatic, and thyroid metastases showed that RCC cells express membranous somatostatin receptor 2. These findings indicate that 68Ga-DOTATOC PET/CT can be used as a new imaging modality in management of metastatic RCC and might contribute to the development of new somatostatin analogue-based methods for the treatment of metastatic RCC.
ISSN:1558-7673
1938-0682
1938-0682
DOI:10.1016/j.clgc.2018.03.011